Premium
Monitoring cancer through the blood
Author(s) -
Paweletz Cloud P.,
Jänne Pasi A.
Publication year - 2014
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.28967
Subject(s) - medicine , genotyping , blood cancer , cancer , disease monitoring , genotype , gold standard (test) , disease , oncology , intensive care medicine , pathology , gene , genetics , biology
Tumor biopsies remain the gold standard for the evaluation of genetic changes in tumors either at diagnosis or after treatment with targeted therapies. However, this is not always feasible and can seldom be performed more than once. Noninvasive techniques that measure the allelic burden in blood have the potential to realize genotype‐directed cancer therapy. These technologies can potentially be used for noninvasive tumor genotyping and also provide an opportunity for disease monitoring. Several non‐invasive genotyping technologies are currently under development and being evaluated in patients treated with targeted therapies.